Clinical Trial Detail


Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

Email us at :

NCT ID NCT02511405
Title A Phase 3, Pivotal Trial of VB-111 Plus Bevacizumab vs. Bevacizumab in Patients With Recurrent Glioblastoma (GLOBE)
Acronym GLOBE
Recruitment Completed
Gender both
Phase Phase III
Variant Requirements No
Sponsors Vascular Biogenics Ltd. operating as VBL Therapeutics
Age Groups: adult
Covered Countries USA | CAN

No variant requirements are available.